GlycoEra Revenue and Competitors
Estimated Revenue & Valuation
- GlycoEra's estimated annual revenue is currently $7M per year.
- GlycoEra's estimated revenue per employee is $155,000
Employee Data
- GlycoEra has 45 Employees.
- GlycoEra grew their employee count by 29% last year.
GlycoEra's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Principal Scientist | Reveal Email/Phone |
3 | President and CEO | Reveal Email/Phone |
GlycoEra Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is GlycoEra?
GlycoEra AG is advancing glycoengineered therapeutics to address unmet medical needs. Despite significant advancements in understanding the role of glycans in human health and diseases, this knowledge has not translated well into therapeutic drug development, a consequence of the limitations and complexities of controlling glycosylation processes. GlycoEra's platform has overcome these challenges! The CustomGlycan Platform enables glycan-mediated modes of action through the engineering of highly defined specific glycan structures, accessing a novel combinatorial dimension for the treatment of very challenging diseases. Get in touch with us if you would like to be part of this amazing new era in therapeutic drug development!
keywords:N/AN/A
Total Funding
45
Number of Employees
$7M
Revenue (est)
29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.6M | 48 | 4% | N/A |
#2 | $10.9M | 55 | 41% | N/A |
#3 | $11.9M | 63 | 21% | N/A |
#4 | $11.7M | 78 | -1% | N/A |
#5 | $11.7M | 78 | -1% | N/A |